Stock Taper
SCREENER COMPARE ANY 2 STOCKS
STOK
STOKE THERAPEUTICS, INC.
NASDAQ
$31.62
▼ DOWN 2.98% (-0.97)

KEY STATISTICS

Market Cap$2.04 B
52w High$40.22
52w Low$18.80
Dividend Yield—
Frequency—
P/E-9.47
Volume754.10K
Shares Out.64.53M

COMPANY

LEADERSHIP

Ian F. Smith
CHIEF EXECUTIVE
Ian F. Smith

COMPENSATION 2026

Salary$170,625
Stock Awards$11,590,000
Incentive Plan Pay$0
All Other Comp.$38,838
Total$27,031,655

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 19, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
170

PRICE TARGET

Target High$58.00
Target Low$44.00
Target Median$51.00
Target Consensus$51.00

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$8.21M
NOV
3
TUE

PRICE

$31.62 ▼ DOWN 2.98% (−$0.97)
$31.50$31.80$32.10$32.409:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM31.62

About Stoke Therapeutics, Inc.

https://www.stoketherapeutics.com ↗

Stoke Therapeutics, a Massachusetts-based biotech founded in 2014, develops antisense oligonucleotide medicines like STK-001 for genetic diseases such as Dravet syndrome, utilizing its proprietary approach to precisely upregulate protein expression.

INDUSTRY

Biotechnology

A PRODUCT STOKE THERAPEUTICS, INC. IS KNOWN FOR

zorevunersen (STK-001)
zorevunersen (STK-001)

Zorevunersen, Stoke Therapeutics' lead RNA-based drug in Phase 3 trials, is developed to treat Dravet syndrome, a severe genetic epilepsy.

COMPETITORS

COMPETITOR
ALNY COMPARE
BIIB COMPARE
IONS COMPARE
PTCT COMPARE
WVE COMPARE

Revenue by Products

IconPRODUCTFY2024FY2025
License$29.4M $11.5M ▼
Service$7.2M $4.6M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
159
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.00% · 1.9M
XBI
0.46% · 1.7M
IWM
0.06% · 1.4M
SCHA
0.04% · 268.0K
TCAF
0.08% · 210.8K
DFAS
0.04% · 194.8K
FESM
0.07% · 137.7K
SBIO
1.01% · 76.9K
LABU
0.31% · 61.0K
FYC
0.13% · 56.9K
XRSU.L
0.06% · 50.4K
GNOM
1.13% · 33.3K
PRFZ
0.03% · 27.7K
GSSC
0.07% · 23.4K
WBIO.L
2.01% · 20.5K
BBSC
0.07% · 15.3K
HELX
1.21% · 12.2K
TPSC
0.09% · 11.1K
BBC
0.65% · 10.5K
SGRW
1.15% · 10.4K
HRTS
0.56% · 9.9K
RTWO.L
0.09% · 6.1K
URTY
0.02% · 2.2K
RFLR
0.06% · 1.9K
TILT
0.00% · 1.7K
ESSC
0.10% · 1.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
257
TOP 12 OF 257 · RANKED BY POSITION SIZE
Atp Life Science Ventures, L.P.
17.2M sh · $666.56M
Fmr LLC
6.9M sh · $161.33M
Blackrock, Inc.
6.0M sh · $140.7M
Rtw Investments, LP
5.6M sh · $184M
Blackrock Inc.
5.4M sh · $73.08M
Lynx1 Capital Management LP
5.4M sh · $171.54M
Baker Bros. Advisors LP
4.6M sh · $108.9M
Redmile Group, LLC
4.2M sh · $98.13M
Morgan Stanley
3.5M sh · $112.56M
Wellington Management Group Llp
3.5M sh · $115.15M
Cowen And Company, LLC
3.2M sh · $39.87M
Toronto Dominion Bank
3.2M sh · $103.83M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF MEDICAL OFFICER
Ticho Barry
Sale · 4.5K shares
2026-08-18
★
OFFICER: CHIEF MEDICAL OFFICER
Ticho Barry
Sale · 10.0K shares
2026-08-14
★
DIRECTOR
Kaye Edward M. MD
Sale · 637 shares
2026-08-18
★
OFFICER: GENERAL COUNSEL & CORP SEC
Allan Jonathan
Purchase · 6.0K shares
2026-08-14

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 6
OUTPERFORM 1
NEUTRAL 1
8 GRADES IN THE LAST 12 MONTHS
Wedbush OUTPERFORM Canaccord Genuity BUY Chardan Capital BUY Guggenheim BUY BTIG BUY Needham BUY HC Wainwright & Co. BUY JP Morgan NEUTRAL

SECTORS PEERS

PEERPRICE
SYRE$90.36COMPARE
BCRX$9.82COMPARE
PHVS$35.32COMPARE
ZYME$28.27COMPARE
ZBIO$31.27COMPARE
NTLA$12.87COMPARE
NVAX$9.26COMPARE
WVE$5.04COMPARE